FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	urden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Noiman Silvia						2. Issuer Name and Ticker or Trading Symbol Eloxx Pharmaceuticals, Inc. [ ELOX ]								neck all app  X Direc	icable) or	r 1		0% Owner	
(Last) (First) (Middle) C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET, 4TH FLOOR NORTH						3. Date of Earliest Transaction (Month/Day/Year) 06/15/2018								X Officer (give title Other (specify below)  Chief Executive Officer					
(Street) WALTH		[A tate)	02451 (Zip)		-							Lin	e) X Form Form Persi	′					
1. Title of Security (Instr. 3) 2. Trans Date				sactio			Code (Instr.		ties Acquir	ed (A) or	5. Amo Securi Benefi	5. Amount of 6. Securities Find Beneficially ([		orm: Direct II D) or Indirect E	7. Nature of ndirect Beneficial Ownership				
							(WOITHID AY TEAL)		` <del>  `                                  </del>	v	Amount	t (A) or (D)		Report Transa	Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common	Stock			06/1	5/20	18			A		141,38	89 A	A \$0.00 141,389 D						
			Table II -						uired, Di s, option					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate, T	4. Transaction Code (Instr. ) 8)		Derivative E		6. Date Exercisabl Expiration Date (Month/Day/Year)			7. Title and Amor of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivativ Securitie Beneficia Owned Followin Reported	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Employee Stock Option (Right to Buy)	\$23.27	06/15/2018			A		141,389		06/15/2018	3 0	6/15/2028	Common Stock	141,389	\$0.00	141,3	89	D		
Employee Stock Option (Right to Buy)	\$23.27	06/15/2018			A		40,000		(1)	0	6/15/2028	Common Stock	40,000	\$0.00	40,00	00	D		

## **Explanation of Responses:**

1. One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

## Remarks:

/s/ Gregory Weaver, Attorney in 06/19/2018

**Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.